Detection and Classification of Cardiac Rhythm and Atrial Fibrillation Using a Finger-worn Ring

ClinicalTrials.gov ID: NCT06892938

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT06892938. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:56 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Finger Worn Detection Via Electrocardiographic Ring of Atrial Fibrillation and ECG Waveform Analysis (FINDER-AF)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Everbeat is a finger-worn ring that has a built-in electrocardiogram (ECG). In this study the investigators ensure that the ECG as read by the everbeat correctly classifies heart rhythms and detects atrial fibrillation. Investigators will also correlate the everbeat ECG waveform with a clinical-grade FDA approved electrocardiogram to ensure it may be reliably interpreted by clinicians or other algorithms.

Study identification

NCT ID: NCT06892938
Recruitment status: Active, not recruiting
Study type: Observational
Phase: Not listed
Lead sponsor: Everbeat; Industry
Enrollment: 232 participants

Conditions and interventions

Conditions

Interventions

Atrial Fibrillation Identification Diagnostic Test

Diagnostic Test

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Sep 17, 2024 (Actual)
Primary completion: Mar 12, 2025 (Actual)
Completion: Apr 1, 2025 (Estimated)
Last update posted: Mar 27, 2025

2024 – 2025

United States locations

U.S. sites: 3
U.S. states: 3
U.S. cities: 3

Facility	City	State	ZIP	Site status
XIMED	La Jolla	California	92037	—
Our Lady of Lake Hospital	Baton Rouge	Louisiana	70808	—
Allegheny General Hospital	Pittsburgh	Pennsylvania	15232	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT06892938, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Mar 27, 2025 · Synced Nov 15, 2026